Achieve Life Sciences (NASDAQ:ACHV – Get Rating) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.09, MarketWatch Earnings reports. During the same quarter last year, the firm earned ($1.30) EPS.
Achieve Life Sciences stock opened at $6.64 on Friday. Achieve Life Sciences has a fifty-two week low of $5.62 and a fifty-two week high of $10.40. The firm’s 50-day simple moving average is $7.24 and its 200 day simple moving average is $7.52. The company has a debt-to-equity ratio of 0.53, a quick ratio of 9.80 and a current ratio of 9.80.
Hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. bought a new stake in Achieve Life Sciences in the first quarter worth about $79,000. Raymond James & Associates bought a new stake in Achieve Life Sciences in the first quarter worth about $99,000. BlackRock Inc. raised its position in Achieve Life Sciences by 455.6% in the fourth quarter. BlackRock Inc. now owns 15,207 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 12,470 shares during the period. Citadel Advisors LLC bought a new stake in Achieve Life Sciences in the fourth quarter worth about $149,000. Finally, LPL Financial LLC raised its position in Achieve Life Sciences by 4.7% in the third quarter. LPL Financial LLC now owns 72,000 shares of the biopharmaceutical company’s stock worth $612,000 after acquiring an additional 3,200 shares during the period. 37.27% of the stock is currently owned by institutional investors and hedge funds.
Achieve Life Sciences Company Profile (Get Rating)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
- Get a free copy of the StockNews.com research report on Achieve Life Sciences (ACHV)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 "MUST OWN" Growth Stocks
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.